Poland

In late October 2024, the Agency for Health Technology Assessment and Tariff System (AOTMiT) published several recommendations concerning the Prenatal Testing Program, specifically on removing alpha-fetoprotein and estriol testing and qualifying the placental growth factor (PlGF) test and free fetal DNA testing (cffDNA) as part of non-invasive prenatal diagnostics.

In the fourth quarter of 2023, two new health technology assessments were initiated by the Agency for Health Technology Assessment and Tariff System (AOTMiT). The assessments belong to the cardiovascular and neurovascular technology groups.

In early August 2023, the Polish Agency for Health Technology Assessment and Tariff System (AOTMiT) announced the start of the evaluation of several technologies in men’s health, neuromodulation and in-vitro diagnostics fields.

MTRC expands the coverage of EU countries with its core service of reimbursement analysis (procedure coding, payment model, reimbursement tariffs). Work is done by MTRC personnel, supported by local reimbursement experts. Contact us, if you want to learn more.

On 13th of October of 2017, the Ministry of Health of Poland commissioned Agency of Health Technology Assessment and Tariff Systems (AOTMiT) to assess the benefit of angioplasty of arteries of lower extremities (femoral and popliteal) with drug-eluting balloons.